Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors Acta Pharmacologica Sinica Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives Metabolism Clinical and Experimental Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications